Kenneth Down
About Kenneth Down
Kenneth Down is the Director of Drug Discovery at BenevolentAI and a Scientific Leader and Associate Fellow at GSK, with over 20 years of experience in the pharmaceutical industry.
Director at BenevolentAI
Kenneth Down currently serves as the Director of Drug Discovery at BenevolentAI, based in London, England, United Kingdom. He joined the company in July 2021 and is involved in leveraging AI technology in the drug discovery processes. At BenevolentAI, he is part of a team managing an in-house pipeline of over 25 drug programs.
Current Role at GSK
Kenneth Down holds the position of Scientific Leader and Associate Fellow at GSK, a leading pharmaceutical company. His responsibilities at GSK include overseeing scientific research and contributing to the development of new drugs. His role demands a high level of expertise and significant leadership skills within the scientific community.
Former Principal Scientist at GSK
Kenneth Down worked as a Principal Scientist at GSK from 2004 to 2016, a 12-year tenure based in Stevenage, United Kingdom. During this period, he was heavily involved in pharmaceutical research and development, contributing to various scientific advancements within the company.
Previous Role at OSI Pharmaceuticals
From 2000 to 2004, Kenneth Down was employed at OSI Pharmaceuticals as a Research Scientist. Over these 4 years, he engaged in significant research activities that added to his extensive experience in the pharmaceutical industry.
Expertise in Pharmaceutical Industry
Kenneth Down has accumulated over 20 years of experience in the pharmaceutical industry. His career spans key roles in drug discovery and research at major organizations such as GSK and OSI Pharmaceuticals. His depth of expertise includes developing drug discovery processes that integrate AI technology, underscoring his position as a significant contributor to the field.